Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Active-Controlled Trial of Cell-Derived Influenza Vaccine in Elderly Subjects
2009-014767-40Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine in seasonal influenza and influenza (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Serum haemagglutination inhibition (HI) antibody response 3 weeks after initial vaccination and Serum haemagglutination inhibition (HI) antibody response 3 weeks after revaccination at 1 year. Started Sep 2009; status: completed.
02
Drugs
influenza vaccine
03
Conditions
seasonal influenzainfluenza
Beyond the preview
Go deeper on 2009-014767-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014767-40.